Welcome to Open Science
Contact Us
Home Books Journals Submission Open Science Join Us News Unsubscribe Page
Antibiotic Potential of Cefuroxime (a Second-Generation Cephalosporin Antibiotic) on Nasal Staphylococcus aureus Isolates
Current Issue
Volume 3, 2015
Issue 4 (August)
Pages: 33-38   |   Vol. 3, No. 4, August 2015   |   Follow on         
Paper in PDF Downloads: 23   Since Aug. 28, 2015 Views: 834   Since Aug. 28, 2015
Authors
[1]
Orhue O. P., Department of Microbiology, Faculty of Natural Sciences, Ambrose Alli University, Ekpoma, Edo State, Nigeria.
[2]
Oikhala O. G., Department of Microbiology, Faculty of Natural Sciences, Ambrose Alli University, Ekpoma, Edo State, Nigeria.
[3]
Agbolahor D. E., Department of Microbiology, Faculty of Natural Sciences, Ambrose Alli University, Ekpoma, Edo State, Nigeria.
[4]
Ekundayo A. O., Department of Microbiology, Faculty of Natural Sciences, Ambrose Alli University, Ekpoma, Edo State, Nigeria.
[5]
Oviasojie F. E., Department of Microbiology, Faculty of Natural Sciences, Ambrose Alli University, Ekpoma, Edo State, Nigeria.
Abstract
Bacterial resistance to several antibiotics has become an increasing issue in the treatment of bacterial infections including Staphylococcus aureus (S. aureus); the most common cause of bacterial infections. The problem has resulted to drug discovery and development and consequently, drug classification into generations. This study therefore investigates the antibiotic potential of Cefuroxine (a second generation Cephalosporin’s known to have a broader spectrum than the first-generation) on nasal S. aureus isolates. In a bid to achieve this objective, nasal swab were collected from undergraduate students in Ambrose Alli University, Ekpoma. Following standard laboratory procedures, the minimum inhibitory concentration (MIC) of Cefuroxime was determined and recorded and results presented in simple descriptive statistics and tables. The results showed that S. aureus is a β-Lactamase producing bacterial and that Cefuroxime has antibiotic potential to β-Lactamase producing bacterial. The mean MIC of Cefuroxime was 0.38±0.32µg/ml and ranges from 0.02µg/ml (minimum) to 0.64µg/ml (maximunm). Although the different between the minimum and maximum MICs was statistically significantly (p<0.05), the very low MICs indicated that Cefuroxime is a powerful antibiotic against nasal isolates of S. aureus.
Keywords
Cefuroxine, Antibiotics, Staphylococcus aureus, Nasal Isolates, Apparently Healthy Students
Reference
[1]
Adesida, S.A., Abioyi, O.A., Banero, B.S. ., Brai, B.T.C., Smith, S.I., Amisu, K.O., Ehichioya, D.U., Ogunsola, E.T. and Coker, A.O. (2007). Associated risk factors and pulse-field gel electrophoresis of nasal isolated of Staphylococcus aureus from medical students in a tertiary hospital in Lagos, Nigeria. Brazilian J Infect. Dis., 11(1):
[2]
Adeleke SI and Asani MO. (2009). Urinary tract infection in children with nephritic syndrome in Kano, Nigeria. Annual African Medicine. 8: 38-41.
[3]
Agbonlahor, D.E and Adegbola, R.A. Mechanism of bacterial resistance to antibiotics. In: Uzoma, K.C., Nwobu, R; Adedeji, S.O. eds Medical Bacteriology 2nd ed. Commercial Press. Benin City. 1996, Pp 89-91.
[4]
Anah MU, Udo JJ, Ochigbo SO, Abia-Bassey LN. Neonatal septicaemia in calabar, Nigeria. Trop. Doct. 2008; 38: 126-128.
[5]
Baliga, S., Bansil, R., Suchitra, V., Bharati, B., Vidyaniketan, K. and Shenoy, S. (2007). Nasal carriage of MRSA in medical students. J. Hosp. Infect., 91-92.
[6]
Bekibele CO, Kehinde AO, Ajayi BG. Upper lid skin bacterial count of surgical eye patients in Ibadan, Nigeria. African Journal of Medicine and Medical Sciences. 2009; 37: 273-277.
[7]
Calderon, C.B. and Sabundayo, B.P. (2007). “Antimicrobial classification”: Dr. for. Bug.10(2): 99-123.
[8]
Carrizosa J, KobasaWD, Kaye D. Effectiveness of nafcillin, methicillin, cephalothin in experimental Staphylococcus aureus endocarditis. Antimicrob Agents Chemother 1979;15:735-737.
[9]
Chambers HF. Evaluation of ceftobiprole in a rabbit model of aortic valve endocarditis due to methicillin-resistant and vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother 2005;49:884-888.
[10]
Cruickshank, R., Duguid, J.P., Marmiun, J.P and Swam, R.H. (1975), Staphylococcus aureus, Medical Micro biology -13th edition. Livingston Publishers Pp 236-245.
[11]
Fong IW, Engelking ER, Kirby WM. Relative inactivation by Staphylococcus aureus of eight cephalosporin antibiotics. Antimicrob Agents Chemother 1976;9:939-944.
[12]
Glinka T, Huie K, Cho A, Ludwikow M, Blais J, Griffith D, Hecker S, Dudley M. Relationships between structure, antibacterial activity, serum stability, pharmacokinetics and efficacy in 3-(heteroarylthio) cephems. Discovery of RWJ-333441 (MC-04,546).Bioorg Med Chem 2003;11:591-600.
[13]
Hanan F, Eid M, Abdel-Al A and Kotb I (2005). Antibiotic Resistance Pattern of Staphylococcus aureusin Furunculosis. J Pan-Arab League of Dermatol.17(1):71-81
[14]
Highet AS, Hay RJ and Robert S (1992).Bacterial Infections. In: Textbook of Dermatology. Edited by Champion RH, Burton JL and EblingFJG. 5th Ed. Blackwell Scientific Publication, Oxford. 2: 953-1030
[15]
Karchmer, A.W. (2000). Cephalosporins, Principles and practices of infectious diseases. Clin. Infect. Dis. pp 274-291.
[16]
Kolawole DS, Stratton CW, Zygmunt DJ. Characterisation of four BetaLactamases produced by Staphylococcus aureus. Antimicrobial Agents and Chemotherapy 1992; 36: 440-5.
[17]
Kucers, A., and Benelt, N. (2004).The use of Antibiotics. A comprehensive Review with clinical emphasis Pp. 201-208.
[18]
Lamikanra, B. D. Paul, O. B. Akinwole and M. O. Paul (2006) Nasal carriage of Staphylococcus aureus in a population of healthy Nigerian students., J Med Microbiol 55 , 317-324.
[19]
Livorsi D J E, Crispell C S W, Satola E. M. Burd R, Jerris Y F, Wang E G, et al.(2012). Prevalence of blaZ Gene Types and the Inoculum Effect with Cefazolin among Bloodstream Isolates of Methicillin-Susceptible S. aureus Antimicrobial Agents and Chemotherapy; 56 (8):4474–7.
[20]
Lowry FD. Staphylococcus aureus Infection. New Engl. J. Med. 1998; 339: 520-532.
[21]
Masroor A, Baqir S N, Muhammad H S, Dilnawaz S, and Khursheed H (2002). Comparative Antimicrobial Evalulation of Cephalosporins and Quinolnes in common Pediatric infections, Pakistan Journal of Pharmaceutical Sciences; 15(2):13-19.
[22]
Mostafizur R, Abdul HK, Shahjahan M, DipakKP and Pervez H (2005).Antibiotic Susceptibility and R- Plasmid Mediated Drug Resistance in Staphylococcus aureus. Med J Islamic World Acad Sci. 15(3)111-116
[23]
Odetoyin WB, Aboderin AO, Ikem RT, Kolawole BA, Oyelese AO. Asymptomatic bacteriuria in patients with diabetes mellitus in Ile-Ife, South-West Nigeria. East African Journal of Medicine. 2008; 85: 18-23.
[24]
Onipede AO, Onayade AA, Elusiyan JB, Obiajunwa PO, Ogundare EO, Olaniran OO, Adeyemi LA, Oyelami OO (. Invasive bacterial isolates from children with severe infections in Nigerian hospital. J. Infec. Dev. Ctries. 2009; 2: 429-436.
[25]
Orhue, P.O. and Momoh A.R.M. (2012). The antibiogram types of Staphylococcus aureus isolated from nasal carriers from irrua Specialist teaching hospital, Edo state, Nigeria. E3 Journal of Biotechnology and Pharmaceutical Research Vol. 3(4), pp. 83-87.
[26]
PlestedSJ, Simpson IN, James M. (1983). The Detection of Bacterial β- Lactamase and their Identification by Analytical Isoelectric focusing. In: Russel AD and Quensel LB. editors. Antibiotics: Assessment and Antimicrobial Activity and Resistance. London: Academic Press 1983; 111-26.
[27]
Quinn EL, Pohlod D, Madhavan T, Burch K, Fisher E, Cox F. Clinical experiences with cefazolin and other cephalosporins in bacterial endocarditis. J Infect Dis 1973;128 (Suppl):S386-391.
[28]
Regamey C, Libke RD, Engelking ER, Clarke JT, Kirby MM. Inactivation of cefazolin, cephaloridine, and cephalothin by methicillin-sensitive and methicillin-resistant strains of Staphylococcus aureus. J Infect Dis 1975;131:291-294.
[29]
Santhosh, DV., Shobha, KL., Bairy, I., Rao, G., Anand, KM and D’ Souza, J: Nasal screening and survey of pre-clinical medical students from Malaysia for nasal carriage of coagulase positive MRSA and rate of nasal colonization with Staphylococcus species Journal of Clinical and Diagnostic Research. 2007 Dec; 1(6):494-499.
[30]
Sasikala S., Ramganesh S. andSundararaj T. (2011). Drugresistance of Staphylococcus aureus in sinusitis patients. International Journal of Biosciences; Vol. 1, No. 3, p. 63-71.
[31]
Shanmugam J., Gopal R., Kumar S.S. (2009). The prevalence, antibiogram and characterisation of staphylococcus aureus including MRSA among the healthy staff, medical students and patients from Sri ManakulaVinayagar Medical College and Hospital (SMVMCH), Puducherry. DSTE project report (Government of Puducherry).
[32]
SteckelbergJM, Rouse MS, Tallan BM, OsmonDR, Henry NK, Wilson WR. Relative efficacies of broad-spectrum cephalosporins for treatment of methicillin-susceptible Staphylococcus aureus experimental infective endocarditis. Antimicrob Agents Chemother 1993;37:554-558.
[33]
SuhailY.E.A and Sulieman M.E. (2014). Susceptibility of Hospital Staphylococcus aureus Isolates AgainstCephalosporins Using Manual E-test. Journal of Natural and Medical Sciences; vol. 15 (2): 36- 43.
[34]
Todar K (2008). Staphylococcus aureus and Staphylococcal Disease. Todar’s Online Textbook of Bacteriology. http://www.textbookofbacteriology.net/staph.htm
[35]
Turnidge J, Chang FY, Fowler VG. Staphylococcus aureus.Antimicro-bial Therapy and Vaccines; 2002;2:631-58.
[36]
Vouillamoz J, EntenzaJM, Hohl P, Moreillon P. LB11058, a new cephalosporin with high penicillin-binding protein 2a and activity in experimental endocarditis due to homogeneously methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2004;48:4322-4327.
[37]
Washington J A, Jones R N, Gerlach E H, Murray P R, Allen S D, and Knapp C.C (1993). Multicenter Comparison of In Vitro Activities of FK-037, Cefepime, Ceftriaxone, Ceftazidime, and Cefuroxime, Antimicrobial Agents and Chemotherapy; 37(8):1696-1700.
Open Science Scholarly Journals
Open Science is a peer-reviewed platform, the journals of which cover a wide range of academic disciplines and serve the world's research and scholarly communities. Upon acceptance, Open Science Journals will be immediately and permanently free for everyone to read and download.
CONTACT US
Office Address:
228 Park Ave., S#45956, New York, NY 10003
Phone: +(001)(347)535 0661
E-mail:
LET'S GET IN TOUCH
Name
E-mail
Subject
Message
SEND MASSAGE
Copyright © 2013-, Open Science Publishers - All Rights Reserved